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Introduction: Ductal adenocarcinoma is a rare variety of the common acinar adenocarcinoma. It usually presents
with refractory symptoms, and during cystoscopy, it is seen as an exophytic lesion at the area of the
verumontanum.
Case presentation: An 82-year-old Caucasian man was diagnosed with ductal adenocarcinoma of the prostate
after undergoing transurethral resection of the prostate for urinary retention. Immunohistochemistry confirmed the
nature of the tumor. The patient was treated with triptorelin, 3.75 mg once/month, and bicalutamide, 50 mg 1 × 1.
The serum prostate-specific antigen at three, six and 12 months after transurethral resection of the prostate was 0.1
ng/ml. The patient remains asymptomatic, and he entered a six-month follow-up protocol.
Conclusion: Ductal adenocarcinoma often involves the central ducts of the gland and may present as an
exophytic papillary lesion in the prostatic urethra. This is why it usually presents with refractory symptoms. The
outcome for men with prostatic ductal adenocarcinoma is, in most studies, worse than the outcome for men with
prostatic acinar adenocarcinoma. Aggressive management is indicated, even with low-volume metastatic disease.
Introduction
Ductal carcinoma of the prostate was originally identified
by Melicow and Pachter in 1967. Thought initially to be
a neoplastic proliferation of remnant paramesonephric
tissue, it was given the name endometrioid carcinoma.
More extensive pathologic analysis, including ultrastruc-
tural studies, determined that these tumors, however, ori-
g i n a t ef r o mt h ep r o s t a t ea n da r en o wm o r ec o r r e c t l y
termed ductal carcinoma, as a variant of the common
acinar adenocarcinoma. We present a case of ductal ade-
nocarcinoma, which, during cystoscopy, was missing the
characteristic exophytic lesion and looked like a flat, red-
dish, edematous area at the prostatic urethra.
Case presentation
An 82-year-old Caucasian man arrived at the emergency
department of our hospital complaining of painless,
total, macroscopic hematuria starting 24 hours ago.
His medical history includes some lower urinary tract
symptoms, starting six years ago, insulin-dependent
diabetes mellitus, and an episode of stroke five years
ago. Clinical examinations were normal, and digital
rectal examination (DRE) was negative for pathologic
findings. The estimated prostate volume was 70 ml.
The laboratory findings were normal, and total serum
PSA was 3.7 ng/ml.
At the abdominal ultrasound, the prostate volume was
calculated as 65 ml, and the residual volume was 45 ml.
During cystoscopy, the bladder mucosa had a normal
macroscopic appearance and an enlarged prostatic mid-
dle lobe with small areas of hemorrhage was noted.
The patient left the hospital with finasteride, 5 mg 1 × 1,
and tamsulosin, 0.4 mg 1 × 1. Three months later, the
serum PSA was 2.9 ng/ml.
Five months later, the patient returned to the emer-
gency department for urinary retention. An 18F Foley
catheter was inserted, and 15 days later, the patient had
a transurethral resection of the prostate (TURP). During
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prostate, especially at the area of the prostatic urethra
proximal to the verumontanum. The redness involved
the bladder neck, the area of the triangle, and the left
lateral bladder wall. The same area was characterized by
diffuse edema. The prostatic lateral and middle lobes
were removed and cold-cup biopsies were taken from
the edematous area of the bladder neck and lateral wall.
The histologic examination showed ductal prostatic ade-
nocarcinoma (Figures 1 and 2). The CT scan of upper
and lower abdomen and thorax and the bone scan were
negative for metastasis.
The patient was treated with triptorelin, 3.75 mg
once/month and bicalutamide, 50 mg 1 × 1. The serum
PSA at three, six, and 12 months after TURP was 0.1
ng/ml. The patient remains asymptomatic, and he
entered a six-month follow-up protocol.
Discussion
This tumor accounts for fewer than 1% of prostatic ade-
nocarcinomas (as a dominant pattern) and has been
referred to under a number of different names including
endometrioid and papillary carcinoma [1]. The incidence
of ductal adenocarcinoma, including both pure ductal
and mixed ductal-acinar adenocarcinomas, is 3.2% of all
prostatic carcinomas. Clinically, ductal adenocarcinoma
often involves the central ducts of the gland and may pre-
sent as an exophytic papillary lesion in the prostatic ure-
thra. For this reason, they are often seen in transurethral
resection (TUR) specimens and at radical prostatectomy
(RP), and are less often found in needle biopsies. When
diagnosed by needle biopsy, more than 50% of the
patients will have high-volume disease with a higher fre-
quency of advanced pathologic stage and a shorter time
to progression. The tumor presents in elderly men (age
range, 65 to 87 years) with hematuria or obstructive
symptoms due to a prostatic urethral mass [2]. The digi-
tal rectal examination is usually abnormal and often sug-
gestive of malignancy, with an enlarged and nodular
prostate gland. PSA is expressed by ductal carcinoma
cells but is not elevated in all patients. The possibility of
PSA production in an associated acinar component also
makes interpretation of the PSA difficult and, as such, a
normal serum PSA before surgery does not allow predic-
tion of the final pathologic stage. PSA cannot reliably be
used to risk stratify patients [3]. A recent report suggests
that because most ductal adenocarcinomas secrete PSA,
they may be more likely to produce unusual serum mar-
kers, such as carcinoembryonic antigen [4]. Ductal ade-
nocarcinomas have a more aggressive clinical course and
must be diagnostically separated from pure acinar adeno-
carcinoma. Varying reports concerned serum PSA mea-
surements in cases with a predominant ductal pattern,
with some indicating a lower level than might otherwise
be expected.
The clinical macroscopic appearance of ductal adeno-
carcinoma by cystourethroscopy, is, in many cases, that
of an exophytic, villous/polypoid growth, with white
fronds of “worm-like” tumor protruding into the urethra
at or near the verumontanum. The prostatic urethra can
also appear narrowed, nodular, or normal. Ductal ade-
nocarcinoma spreads outside the prostate gland in the
same fashion as pure acinar adenocarcinoma. The papil-
lary and/or cribriform growths can involve periprostatic
soft tissue, seminal vesicles, pelvic lymph nodes, and dis-
tant sites, including lung and bone. Ductal adenocarci-
noma appears to have a propensity to metastasize to
testis, penis, and lung [4].
The outcome for men with prostatic ductal adenocar-
cinoma is, in most studies, worse than the outcome for
men with prostatic acinar adenocarcinoma. Survival and
response to therapy appear to be related to stage. Many
patients with prostatic ductal adenocarcinoma present
with large tumors and advanced stage, including bony
metastasis; this may account for the relatively poor
prognosis. Some patients respond to radical prostatect-
omy, hormonal therapy, and radiotherapy. Factors other
than stage that predict outcome have not been well-
characterized. Aggressive management is indicated, even
with low-volume metastatic disease.
Conclusion
Ductal adenocarcinoma accounts for less than 1% of
prostatic adenocarcinomas as a dominant pattern. Duc-
tal adenocarcinomas have a more-aggressive clinical
Figure 1 Ductal adenocarcinoma of the prostate.
Figure 2 Ductal adenocarcinoma of the prostate.
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Page 2 of 3course and must be diagnostically separated from pure
acinar adenocarcinoma. Ductal adenocarcinoma often
involves the central ducts of the gland and, for this rea-
son, they are often seen in transurethral resection
(TUR) specimens. It usually presents with refractory
symptoms, and during cystoscopy, it is seen as an exo-
phytic lesion at the area of the verumontanum. In our
case, the cystoscopic appearance was unusual, and dur-
ing the operation, we found a diffuse redness at the
whole prostate and especially at the area of the prostatic
urethra proximal to the verumontanum.
Aggressive management is indicated, even with low-
volume metastatic disease.
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